| The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection | Annals of the Rheumatic Diseases | 2009 | 1.9K |
| The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis | Annals of the Rheumatic Diseases | 2009 | 800 |
| EULAR recommendations for the management of primary small and medium vessel vasculitis | Annals of the Rheumatic Diseases | 2009 | 707 |
| Just released from the ASAS factory! First steps towards a disease activity score for ankylosing spondylitis | Annals of the Rheumatic Diseases | 2009 | 597 |
| MicroRNA-146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins | Arthritis and Rheumatism | 2009 | 590 |
| Matrix metalloproteinase 13-deficient mice are resistant to osteoarthritic cartilage erosion but not chondrocyte hypertrophy or osteophyte development | Arthritis and Rheumatism | 2009 | 556 |
| Modification and validation of the Birmingham Vasculitis Activity Score (version 3) | Annals of the Rheumatic Diseases | 2009 | 555 |
| The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal | Annals of the Rheumatic Diseases | 2009 | 543 |
| Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI group | Annals of the Rheumatic Diseases | 2009 | 538 |
| Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis | Annals of the Rheumatic Diseases | 2009 | 536 |
| Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases | Arthritis Research and Therapy | 2009 | 526 |
| Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry | Arthritis and Rheumatism | 2009 | 479 |
| Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study | Arthritis and Rheumatism | 2009 | 467 |
| Cartilage homeostasis in health and rheumatic diseases | Arthritis Research and Therapy | 2009 | 464 |
| Measuring shoulder function: a systematic review of four questionnaires | Arthritis and Rheumatism | 2009 | 463 |
| The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort | Arthritis and Rheumatism | 2009 | 459 |
| MicroRNA-140 is expressed in differentiated human articular chondrocytes and modulates interleukin-1 responses | Arthritis and Rheumatism | 2009 | 457 |
| EULAR recommendations for the management of large vessel vasculitis | Annals of the Rheumatic Diseases | 2009 | 448 |
| Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate | Annals of the Rheumatic Diseases | 2009 | 445 |
| Stromal cell-derived factor 1/CXCR4 signaling is critical for the recruitment of mesenchymal stem cells to the fracture site during skeletal repair in a mouse model | Arthritis and Rheumatism | 2009 | 443 |
| EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR) | Annals of the Rheumatic Diseases | 2009 | 440 |
| The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo | Arthritis and Rheumatism | 2009 | 436 |
| Development and validation of a composite disease activity score for juvenile idiopathic arthritis | Arthritis and Rheumatism | 2009 | 424 |
| A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus | Arthritis and Rheumatism | 2009 | 424 |
| Proposal for a new clinical entity, IgG4-positive multiorgan lymphoproliferative syndrome: analysis of 64 cases of IgG4-related disorders | Annals of the Rheumatic Diseases | 2009 | 419 |
